Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
24.2M
-
Shares change
-
+3.07M
-
Total reported value, excl. options
-
$1.21B
-
Value change
-
+$158M
-
Put/Call ratio
-
2.54
-
Number of buys
-
84
-
Number of sells
-
-56
-
Price
-
$50.12
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2017
186 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2017.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.2M shares
of 207M outstanding shares and own 11.65% of the company stock.
Largest 10 shareholders include Meditor Group Ltd (2.29M shares), Pentwater Capital Management LP (2.24M shares), BB BIOTECH AG (2.1M shares), BlackRock Inc. (1.52M shares), FMR LLC (1.34M shares), STATE STREET CORP (1.26M shares), CREDIT SUISSE AG/ (1.06M shares), VANGUARD GROUP INC (880K shares), Aisling Capital LLC (837K shares), and DISCOVERY CAPITAL MANAGEMENT, LLC / CT (783K shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.